Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): A systematic review and meta-analysis

European Journal of Preventive Cardiology

Volumn 22, Issue 11, 2015, Pages 1435-1441

  Ballocca, Flavia ^a   D'Ascenzo, Fabrizio ^a   Moretti, Claudio ^a   Omedè, Pierluigi ^a   Cerrato, Enrico ^a   Barbero, Umberto ^a   Abbate, Antonio ^b   Bertero, Maria Tiziana ^c   Zoccai, Giuseppe Biondi ^d   Gaita, Fiorenzo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c MAURIZIANO HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

cardiovascular events; predictors; Systemic lupus erythematosus

Indexed keywords

ANTITHROMBOCYTIC AGENT; IMMUNOSUPPRESSIVE AGENT; STEROID;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ACTIVITY; DYSLIPIDEMIA; FAMILY HISTORY; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; NEUROLOGIC DISEASE; PREDICTION; PRIORITY JOURNAL; REVIEW; SMOKING; STENT THROMBOSIS; STEROID THERAPY; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; META ANALYSIS; MIDDLE AGED; MORTALITY; ODDS RATIO; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ADULT; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84944198762     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487314546826     Document Type: Review

References (30)

1. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in during a 5-year period: a multicenter prospective study of 1000 patients. Medicine 1999; 78: 167-175.
2. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-2557.
3. Pirro M, Stingeni L, Vaudo G et al. Systemic inflammation and imbalance between endothelial injury and repair in patients with psoriasis are associated with preclinical atherosclerosis. Eur J Prev Cardiol. Epub ahead of print 6 June 2014. DOI: 10.1177/2047487314538858.
4. Awan Z, Genest J. Inflammation modulation and cardiovascular disease prevention. Eur J Prev Cardiol. Epub ahead of print 7 April 2014. DOI: 10.1177/2047487314529350.
5. Mok CC, Tang SS, To CH, et al. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005; 52: 2774-2782.
6. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-2337.
7. Boucelma M, Haddoum F, Chaudet H, et al. Cardiovascular risk and lupus disease. Int Angiol 2011; 30: 18-24.
8. Shoenfield Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-3347.
9. Rhew EY, Ramsey-Goldman R,. Premature atherosclerosis disease in systemic lupus erythematosus: role of inflammatory mechanism. Autoimmun Rev 2006; 5: 101-105.
10. Salomon JE, Roman MJ,. Subclinical atherosclerosis in rheumatoid disease arthritis and SLE. Am J Med 2008; 121: S3-S8.
11. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801-1808.
12. Bertoli AM, Vilá LM, Alarcón GS, et al. Factors associated with arterial vascular events in PROFILE: a Multiethnic Lupus Cohort. Lupus 2009; 18: 958-965.
13. Burgos PI, McGwin Jr G, Reveille JD, et al. Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). Rheumatology (Oxford) 2010; 49: 1720-1725.
14. Kaiser R, Cleveland CM, Criswell LA, et al. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009; 68: 238-241.
15. Nikpour M, Urowitz MB, Ibanez D, et al. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. Arthritis Res Ther. 2011; 13: R156-R156.
16. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-1900.
17. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700-b2700.
18. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
19. Higgins JPT, Green S (eds) Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2 (updated September 2009). The Cochrane Collaboration 2009 (available from www.cochrane-handbook.org).
20. Wilczynski NL, Haynes RB,. for the Hedges Team. Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: an analytic survey. BMC Med 2004; 2: 23-23.
21. Bertsias G, Ioannidis JP, Boletis J, et al. Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205.
22. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-1725.
23. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
24. Ross JS, Mulvey GK, Stauffer B, et al. Statistical models and patient predictors of readmission for heart failure: a systematic review. Arch Intern Med 2008; 168: 1371-1386.
25. Ward MM, Studenski S,. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch Intern Med 1992; 152: 2082-2088.
26. Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic effects of smoking. Chest 2007; 131: 1557-1566.
27. Lockshin MD,. Update on antiphospholipid syndrome. Bull NYU Hosp Jt Dis 2006; 64: 57-59.
28. Afeltra A, Vadacca M, Conti L, et al. Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors. Arthritis Rheum 2005; 53: 452-459.
29. Buckley T1, Morel-Kopp MC, Ward C, et al. Inflammatory and thrombotic changes in early bereavement: a prospective evaluation. Eur J Prev Cardiol 2012; 19: 1145-1152.
30. Cerrato E1, D'Ascenzo F, Biondi-Zoccai G, et al. Acute coronary syndrome in HIV patients: from pathophysiology to clinical practice. Cardiovasc Diagn Ther 2012; 2: 50-55.